AAPL352.78-3.49 (-0.98%) ▼|ABBV294.55-0.48 (-0.16%) ▼|ABT107.45-1.07 (-0.99%) ▼|ACN247.70-2.79 (-1.11%) ▼|ADBE246.00+2.92 (+1.20%) ▲|AMAT350.25-20.25 (-5.47%) ▼|AMD504.28-29.78 (-5.58%) ▼|AMGN462.32-3.35 (-0.72%) ▼|AMT190.74-0.90 (-0.47%) ▼|AMZN257.75-8.91 (-3.34%) ▼|AVGO333.40-13.61 (-3.92%) ▼|AXP319.05-1.55 (-0.48%) ▼|BA165.22-6.28 (-3.66%) ▼|BAC50.08-0.94 (-1.84%) ▼|BKNG157.53-2.05 (-1.28%) ▼|BLK1,197.97-24.94 (-2.04%) ▼|BMY62.93-0.50 (-0.79%) ▼|BNY151.69-1.72 (-1.12%) ▼|BRK-B592.85-0.09 (-0.02%) ▼|C121.32-2.69 (-2.17%) ▼|CAT570.49-29.71 (-4.95%) ▼|CL100.99+1.32 (+1.32%) ▲|CMCSA25.60+0.44 (+1.75%) ▲|COF193.22-1.06 (-0.55%) ▼|COP140.52-0.83 (-0.59%) ▼|COST1,113.74+7.53 (+0.68%) ▲|CRM214.83-3.01 (-1.38%) ▼|CSCO94.52-1.12 (-1.17%) ▼|CVS88.59-0.76 (-0.85%) ▼|CVX217.14-2.75 (-1.25%) ▼|DE653.99-19.55 (-2.90%) ▼|DHR229.91-3.11 (-1.33%) ▼|DIS118.70-0.27 (-0.23%) ▼|DUK130.59+1.43 (+1.11%) ▲|EMR160.65-5.73 (-3.44%) ▼|FDX327.65+3.51 (+1.08%) ▲|GD359.69-3.77 (-1.04%) ▼|GE325.18-6.63 (-2.00%) ▼|GEV763.57-39.56 (-4.93%) ▼|GILD167.58-0.50 (-0.30%) ▼|GM83.67-2.33 (-2.71%) ▼|GOOG281.26-11.26 (-3.85%) ▼|GOOGL283.72-12.05 (-4.07%) ▼|GS891.54-25.02 (-2.73%) ▼|HD347.51-1.18 (-0.34%) ▼|HON217.95-4.51 (-2.03%) ▼|IBM242.51-4.62 (-1.87%) ▼|INTC55.47-4.19 (-7.02%) ▼|INTU345.56+3.86 (+1.13%) ▲|ISRG437.75-5.84 (-1.32%) ▼|JNJ282.55-3.20 (-1.12%) ▼|JPM338.21-7.98 (-2.31%) ▼|KO99.48+0.23 (+0.23%) ▲|LIN523.46-2.60 (-0.49%) ▼|LLY1,431.67-11.83 (-0.82%) ▼|LMT585.21-10.83 (-1.82%) ▼|LOW224.93-2.80 (-1.23%) ▼|LRCX210.83-15.09 (-6.68%) ▼|MA661.71+0.52 (+0.08%) ▲|MCD274.67+2.70 (+0.99%) ▲|MDLZ67.54+0.00 (+0.00%) ▲|MDT102.88+0.02 (+0.02%) ▲|META626.41-15.28 (-2.38%) ▼|MMM181.68-1.98 (-1.08%) ▼|MO78.90+0.26 (+0.33%) ▲|MRK144.46-3.30 (-2.23%) ▼|MS185.57-5.08 (-2.66%) ▼|MSFT517.99-5.89 (-1.12%) ▼|MU719.02-59.29 (-7.62%) ▼|NEE85.34+0.22 (+0.26%) ▲|NFLX60.75-1.40 (-2.25%) ▼|NKE38.26+0.27 (+0.71%) ▲|NOW99.37-2.88 (-2.82%) ▼|NVDA156.14-6.71 (-4.12%) ▼|ORCL119.09-6.26 (-4.99%) ▼|PEP146.43+0.99 (+0.68%) ▲|PFE28.86-0.03 (-0.10%) ▼|PG173.02+3.22 (+1.90%) ▲|PLTR160.39-7.60 (-4.52%) ▼|PM196.04-2.92 (-1.47%) ▼|QCOM168.52-3.95 (-2.29%) ▼|RTX194.89-3.69 (-1.86%) ▼|SBUX108.72+2.28 (+2.14%) ▲|SCHW92.94-0.04 (-0.04%) ▼|SO94.64+1.81 (+1.95%) ▲|SPG232.78-0.19 (-0.08%) ▼|T22.36+0.18 (+0.81%) ▲|TMO691.33-8.89 (-1.27%) ▼|TMUS170.01+0.06 (+0.04%) ▲|TSLA379.74-10.48 (-2.69%) ▼|TXN294.21-9.39 (-3.09%) ▼|UBER69.99+0.30 (+0.43%) ▲|UNH412.02+4.56 (+1.12%) ▲|UNP303.71+1.27 (+0.42%) ▲|UPS111.82+1.06 (+0.96%) ▲|USB60.43-0.56 (-0.92%) ▼|V426.46+0.70 (+0.16%) ▲|VZ46.34-0.02 (-0.04%) ▼|WFC84.84-1.21 (-1.41%) ▼|WMT128.41+0.32 (+0.25%) ▲|XOM166.87-2.65 (-1.56%) ▼|AAPL352.78-3.49 (-0.98%) ▼|ABBV294.55-0.48 (-0.16%) ▼|ABT107.45-1.07 (-0.99%) ▼|ACN247.70-2.79 (-1.11%) ▼|ADBE246.00+2.92 (+1.20%) ▲|AMAT350.25-20.25 (-5.47%) ▼|AMD504.28-29.78 (-5.58%) ▼|AMGN462.32-3.35 (-0.72%) ▼|AMT190.74-0.90 (-0.47%) ▼|AMZN257.75-8.91 (-3.34%) ▼|AVGO333.40-13.61 (-3.92%) ▼|AXP319.05-1.55 (-0.48%) ▼|BA165.22-6.28 (-3.66%) ▼|BAC50.08-0.94 (-1.84%) ▼|BKNG157.53-2.05 (-1.28%) ▼|BLK1,197.97-24.94 (-2.04%) ▼|BMY62.93-0.50 (-0.79%) ▼|BNY151.69-1.72 (-1.12%) ▼|BRK-B592.85-0.09 (-0.02%) ▼|C121.32-2.69 (-2.17%) ▼|CAT570.49-29.71 (-4.95%) ▼|CL100.99+1.32 (+1.32%) ▲|CMCSA25.60+0.44 (+1.75%) ▲|COF193.22-1.06 (-0.55%) ▼|COP140.52-0.83 (-0.59%) ▼|COST1,113.74+7.53 (+0.68%) ▲|CRM214.83-3.01 (-1.38%) ▼|CSCO94.52-1.12 (-1.17%) ▼|CVS88.59-0.76 (-0.85%) ▼|CVX217.14-2.75 (-1.25%) ▼|DE653.99-19.55 (-2.90%) ▼|DHR229.91-3.11 (-1.33%) ▼|DIS118.70-0.27 (-0.23%) ▼|DUK130.59+1.43 (+1.11%) ▲|EMR160.65-5.73 (-3.44%) ▼|FDX327.65+3.51 (+1.08%) ▲|GD359.69-3.77 (-1.04%) ▼|GE325.18-6.63 (-2.00%) ▼|GEV763.57-39.56 (-4.93%) ▼|GILD167.58-0.50 (-0.30%) ▼|GM83.67-2.33 (-2.71%) ▼|GOOG281.26-11.26 (-3.85%) ▼|GOOGL283.72-12.05 (-4.07%) ▼|GS891.54-25.02 (-2.73%) ▼|HD347.51-1.18 (-0.34%) ▼|HON217.95-4.51 (-2.03%) ▼|IBM242.51-4.62 (-1.87%) ▼|INTC55.47-4.19 (-7.02%) ▼|INTU345.56+3.86 (+1.13%) ▲|ISRG437.75-5.84 (-1.32%) ▼|JNJ282.55-3.20 (-1.12%) ▼|JPM338.21-7.98 (-2.31%) ▼|KO99.48+0.23 (+0.23%) ▲|LIN523.46-2.60 (-0.49%) ▼|LLY1,431.67-11.83 (-0.82%) ▼|LMT585.21-10.83 (-1.82%) ▼|LOW224.93-2.80 (-1.23%) ▼|LRCX210.83-15.09 (-6.68%) ▼|MA661.71+0.52 (+0.08%) ▲|MCD274.67+2.70 (+0.99%) ▲|MDLZ67.54+0.00 (+0.00%) ▲|MDT102.88+0.02 (+0.02%) ▲|META626.41-15.28 (-2.38%) ▼|MMM181.68-1.98 (-1.08%) ▼|MO78.90+0.26 (+0.33%) ▲|MRK144.46-3.30 (-2.23%) ▼|MS185.57-5.08 (-2.66%) ▼|MSFT517.99-5.89 (-1.12%) ▼|MU719.02-59.29 (-7.62%) ▼|NEE85.34+0.22 (+0.26%) ▲|NFLX60.75-1.40 (-2.25%) ▼|NKE38.26+0.27 (+0.71%) ▲|NOW99.37-2.88 (-2.82%) ▼|NVDA156.14-6.71 (-4.12%) ▼|ORCL119.09-6.26 (-4.99%) ▼|PEP146.43+0.99 (+0.68%) ▲|PFE28.86-0.03 (-0.10%) ▼|PG173.02+3.22 (+1.90%) ▲|PLTR160.39-7.60 (-4.52%) ▼|PM196.04-2.92 (-1.47%) ▼|QCOM168.52-3.95 (-2.29%) ▼|RTX194.89-3.69 (-1.86%) ▼|SBUX108.72+2.28 (+2.14%) ▲|SCHW92.94-0.04 (-0.04%) ▼|SO94.64+1.81 (+1.95%) ▲|SPG232.78-0.19 (-0.08%) ▼|T22.36+0.18 (+0.81%) ▲|TMO691.33-8.89 (-1.27%) ▼|TMUS170.01+0.06 (+0.04%) ▲|TSLA379.74-10.48 (-2.69%) ▼|TXN294.21-9.39 (-3.09%) ▼|UBER69.99+0.30 (+0.43%) ▲|UNH412.02+4.56 (+1.12%) ▲|UNP303.71+1.27 (+0.42%) ▲|UPS111.82+1.06 (+0.96%) ▲|USB60.43-0.56 (-0.92%) ▼|V426.46+0.70 (+0.16%) ▲|VZ46.34-0.02 (-0.04%) ▼|WFC84.84-1.21 (-1.41%) ▼|WMT128.41+0.32 (+0.25%) ▲|XOM166.87-2.65 (-1.56%) ▼|
7.7 C
New York
Tuesday, November 17, 2026

Tag: development

Levicept to Present Further Analysis from Phase II Trial of Novel Neurotrophin-3 Inhibitor, LEVI-04, at EULAR

SANDWICH, United Kingdom, June 12, 2025 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis, is to present new data from its large-scale Phase II trial of LEVI-04 at EULAR, the European Congress of Rheumatology in Barcelona, Spain.

Insider information: Carl Haglund appointed as Chief Executive Officer of Aktia Bank Plc

Aktia Bank PlcInsider information12 June 2025 at 9.30 a.m. HELSINKI, June 12, 2025 /PRNewswire/ -- Aktia's Board of Directors has appointed M.Sc (Econ.) Carl Haglund...

Enterome raises $19 million to fund clinical development of its OncoMimics™ immunotherapy to treat Follicular Lymphoma

Paris, France – June 12, 2025

Enterome SA
, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, has raised $19 million in a new private financing to advance its lead clinical program EO2463 OncoMimics™ immunotherapy to treat indolent non-Hodgkin lymphoma (iNHL). The new funds will be used to expand and finalize the ongoing Phase 1/2 SIDNEY clinical trial of EO2463 and prepare the candidate for a registrational trial.

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia...

Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy.

NIRA Dynamics Strengthens Automotive Safety Through Strategic Partnership with BANF Intelligent Tire System

Strategic Partnership Enhances Safety and Efficiency in Trucking SAN FRANCISCO, June 12, 2025 /PRNewswire/ -- Swedish automotive software leader NIRA Dynamics AB is taking vehicle safety...

Real-world prospective data confirms improved risk stratification in multiple myeloma using SKY92 gene expression profiling

According to clinical guidelines, high-risk myeloma patients should receive intensified treatment regimens. However, heterogeneity in clinical markers and staging systems lead to various interpretations of...

KN Energies signs Grant Agreement with the European Commission

International energy terminal operator AB KN Energies (hereinafter – KN, the Company) has signed a Grant Agreement with the European Commission to conduct technical and commercial studies for a planned CO2 terminal in Klaipėda. The terminal is a part of the CCS Baltic Consortium’s cross-border carbon dioxide (CO2) capture, transport and storage value chain currently under development across Lithuania and Latvia.  

Significant efficacy benefit of IMBRUVICA® (ibrutinib) plus venetoclax versus acalabrutinib plus venetoclax in frontline treatment of patients with chronic lymphocytic leukaemia suggested by indirect...

Cross-study findings indicate significant clinical benefit of frontline fixed-duration ibrutinib plus venetoclax with improved likelihood of undetectable minimal residual disease and progression-free survival versus acalabrutinib plus venetoclax1

Trinasolar Hosts “Go Green Walk” in Singapore, Advancing Public Awareness for a Sustainable Future

SINGAPORE, June 12, 2025 /PRNewswire/ -- Trinasolar, a global leader in smart PV and energy storage solutions, successfully held the "Go Green Walk" at...

Global Open Banking Market Size to Reach USD 136.13 Billion by 2030, Growing at a 27.60% CAGR: MarkNtel Advisors (Capgemini, Oracle, Global Payments, Tata...

Global Open Banking Market Report Overview: NEW DELHI, June 12, 2025 /PRNewswire/ -- The Global Open Banking Market size is experiencing significant growth, projected to...

Taboola Unveils DeeperDive, a Gen AI Answer Engine Built for the Open Web, Connecting Readers with Unique Publisher Content, Empowering Publishers to Defy Abuse...

Powered by Taboola's "Pulse of the Internet," Gannett I USA TODAY Network First to Deploy Technology in the U.S., The Independent First to Deploy...

Bigbank AS Results for May 2025

May was a stable month for Bigbank – both the loan and deposit portfolios grew at a steady pace, and profitability remained at a solid level.

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDevelopment